JP2022088597A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022088597A5 JP2022088597A5 JP2022058938A JP2022058938A JP2022088597A5 JP 2022088597 A5 JP2022088597 A5 JP 2022088597A5 JP 2022058938 A JP2022058938 A JP 2022058938A JP 2022058938 A JP2022058938 A JP 2022058938A JP 2022088597 A5 JP2022088597 A5 JP 2022088597A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- human immunoglobulin
- light chain
- nucleic acid
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 41
- 238000000034 method Methods 0.000 claims 40
- 241000283984 Rodentia Species 0.000 claims 33
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 32
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 32
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 29
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 25
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 25
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 claims 24
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 claims 24
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 23
- 101000800646 Homo sapiens DNA nucleotidylexotransferase Proteins 0.000 claims 18
- 210000003719 b-lymphocyte Anatomy 0.000 claims 18
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 12
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 108060003951 Immunoglobulin Proteins 0.000 claims 11
- 210000004602 germ cell Anatomy 0.000 claims 11
- 102000018358 immunoglobulin Human genes 0.000 claims 11
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 10
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 7
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 7
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 7
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 7
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 7
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 241000894007 species Species 0.000 claims 4
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 3
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 claims 2
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 2
- 102100029572 Immunoglobulin kappa constant Human genes 0.000 claims 2
- 101710139965 Immunoglobulin kappa constant Proteins 0.000 claims 2
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 claims 2
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 claims 2
- 102000001183 RAG-1 Human genes 0.000 claims 2
- 108060006897 RAG1 Proteins 0.000 claims 2
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 210000001948 pro-b lymphocyte Anatomy 0.000 claims 2
- 101150008942 J gene Proteins 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000008707 rearrangement Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023074624A JP7586960B2 (ja) | 2016-06-03 | 2023-04-28 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
| JP2024195337A JP2025020339A (ja) | 2016-06-03 | 2024-11-07 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345524P | 2016-06-03 | 2016-06-03 | |
| US62/345,524 | 2016-06-03 | ||
| JP2018563156A JP7053499B2 (ja) | 2016-06-03 | 2017-06-02 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
| PCT/US2017/035731 WO2017210586A1 (en) | 2016-06-03 | 2017-06-02 | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563156A Division JP7053499B2 (ja) | 2016-06-03 | 2017-06-02 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023074624A Division JP7586960B2 (ja) | 2016-06-03 | 2023-04-28 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022088597A JP2022088597A (ja) | 2022-06-14 |
| JP2022088597A5 true JP2022088597A5 (enExample) | 2023-01-18 |
| JP7274018B2 JP7274018B2 (ja) | 2023-05-15 |
Family
ID=59215996
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563156A Active JP7053499B2 (ja) | 2016-06-03 | 2017-06-02 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
| JP2022058938A Active JP7274018B2 (ja) | 2016-06-03 | 2022-03-31 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
| JP2023074624A Active JP7586960B2 (ja) | 2016-06-03 | 2023-04-28 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
| JP2024195337A Pending JP2025020339A (ja) | 2016-06-03 | 2024-11-07 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563156A Active JP7053499B2 (ja) | 2016-06-03 | 2017-06-02 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023074624A Active JP7586960B2 (ja) | 2016-06-03 | 2023-04-28 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
| JP2024195337A Pending JP2025020339A (ja) | 2016-06-03 | 2024-11-07 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10980221B2 (enExample) |
| EP (3) | EP3462853B1 (enExample) |
| JP (4) | JP7053499B2 (enExample) |
| KR (3) | KR102784608B1 (enExample) |
| CN (3) | CN116458475A (enExample) |
| AU (2) | AU2017272337C1 (enExample) |
| BR (1) | BR112018074794A2 (enExample) |
| CA (1) | CA3026088A1 (enExample) |
| CY (1) | CY1126063T1 (enExample) |
| DK (2) | DK4218408T3 (enExample) |
| ES (2) | ES2941810T3 (enExample) |
| FI (2) | FI4218408T3 (enExample) |
| HR (2) | HRP20250471T1 (enExample) |
| HU (2) | HUE061619T2 (enExample) |
| IL (2) | IL263160B2 (enExample) |
| LT (2) | LT4218408T (enExample) |
| MX (3) | MX385681B (enExample) |
| PL (2) | PL4218408T3 (enExample) |
| PT (2) | PT4218408T (enExample) |
| RS (2) | RS64216B1 (enExample) |
| RU (1) | RU2753585C2 (enExample) |
| SG (2) | SG11201810757YA (enExample) |
| SI (2) | SI4218408T1 (enExample) |
| SM (2) | SMT202500152T1 (enExample) |
| WO (1) | WO2017210586A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20181866T1 (hr) | 2013-02-22 | 2019-01-25 | Regeneron Pharmaceuticals, Inc. | Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti |
| KR102784608B1 (ko) | 2016-06-03 | 2025-03-27 | 리제너론 파마슈티칼스 인코포레이티드 | 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물 |
| EP3720279B1 (en) | 2017-12-05 | 2022-09-21 | Regeneron Pharmaceuticals, Inc. | Mice having an engineered immunoglobulin lambda light chain and uses thereof |
| SMT202500038T1 (it) | 2018-03-24 | 2025-03-12 | Regeneron Pharma | Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo |
| CN112566931A (zh) * | 2018-06-13 | 2021-03-26 | 儿童医疗中心有限公司 | 涉及用于抗体发现和/或优化的高通量模型的方法和组合物 |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| BR112021016173A2 (pt) * | 2019-02-22 | 2021-11-03 | Regeneron Pharma | Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma |
| TW202110323A (zh) | 2019-06-05 | 2021-03-16 | 美商再生元醫藥公司 | 具有表現自κ 基因座的有限λ 輕鏈組庫的非人類動物及其用途 |
| WO2021116270A1 (en) * | 2019-12-12 | 2021-06-17 | Dna Script | Chimeric terminal deoxynucleotidyl transferases for template-free enzymatic synthesis of polynucleotides |
| CN111057754B (zh) * | 2019-12-27 | 2021-01-12 | 四川省医学科学院.四川省人民医院实验动物研究所 | 鉴定适用于hbv研究的动物模型的方法和应用 |
| KR20220133248A (ko) | 2020-01-28 | 2022-10-04 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 pnpla3 좌위를 포함하는 비-인간 동물 및 사용 방법 |
| EP4138550A1 (en) * | 2020-04-21 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cxcl13 gene |
| KR20230066386A (ko) | 2020-09-11 | 2023-05-15 | 리제너론 파마슈티칼스 인코포레이티드 | 항원 특이적 항체의 확인 및 제조 |
| CA3199879A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| CA3165366A1 (en) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
| CN118511853A (zh) * | 2021-03-31 | 2024-08-20 | 瑞泽恩制药公司 | 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠 |
| WO2024064860A1 (en) * | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing components of human cellular immune system |
| WO2025250011A1 (en) | 2024-05-29 | 2025-12-04 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment for cancer |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| GB9119338D0 (en) | 1991-09-10 | 1991-10-23 | Inst Of Animal Physiology And | Control of gene expression |
| US5523226A (en) * | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| US5512295A (en) | 1994-11-10 | 1996-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic liposomes for enhanced uptake and delivery |
| US6001349A (en) | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6770291B2 (en) | 1996-08-30 | 2004-08-03 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US7001614B2 (en) | 1996-08-19 | 2006-02-21 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| US7112338B2 (en) | 1997-03-12 | 2006-09-26 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6749863B1 (en) | 1997-11-19 | 2004-06-15 | Georgetown University | Targeted liposome gene delivery |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1379125A4 (en) | 2001-03-22 | 2004-12-08 | Abbott Gmbh & Co Kg | TRANSGENIC ANIMALS THAT EXPRESS SPECIFIC ANTIBODIES FOR INTERESTING GENES AND THEIR USE |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20090042291A1 (en) | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| JP2006514549A (ja) | 2002-12-16 | 2006-05-11 | アメリカ合衆国 | Ｉｌ−１５を発現する組換えワクチンウイルスおよびその使用方法 |
| JP2006518372A (ja) | 2003-01-28 | 2006-08-10 | セレクティス | 脊椎動物の体組織においてエクスビボかつイントトで相同的組換えを誘発するためのメガヌクレアーゼの使用およびその応用 |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| US8218805B2 (en) | 2003-10-11 | 2012-07-10 | Charles Hornback | Wireless speaker system for use with ceiling fans |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| CA2567814C (en) | 2004-05-27 | 2013-07-23 | Jon A. Weidanz | Antibodies as t cell receptor mimics, methods of production and uses thereof |
| DK1802193T3 (da) | 2004-10-19 | 2014-06-10 | Regeneron Pharma | Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| US20060222653A1 (en) | 2004-11-12 | 2006-10-05 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
| EP1858925A2 (en) | 2005-01-12 | 2007-11-28 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| CN103710371B (zh) * | 2005-08-03 | 2017-03-01 | 人类多克隆治疗股份有限公司 | 表达人源化免疫球蛋白的转基因动物中b细胞凋亡的抑制 |
| US20070190063A1 (en) | 2005-08-19 | 2007-08-16 | Bahjat Keith S | Antibody-mediated enhancement of immune response |
| EP4174179B1 (en) | 2005-08-23 | 2025-05-07 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| AU2007235496B2 (en) | 2006-03-31 | 2013-11-21 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| EP2336329B8 (en) | 2007-06-01 | 2012-11-21 | Omt, Inc. | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenis human idiotype antibodies |
| DK2207564T3 (en) | 2007-10-18 | 2017-01-16 | Bavarian Nordic As | USE OF VAT FOR TREATMENT OF PROSTATACANCES |
| US8225343B2 (en) | 2008-01-11 | 2012-07-17 | Sony Computer Entertainment America Llc | Gesture cataloging and recognition |
| PL3456190T3 (pl) | 2008-06-27 | 2022-06-06 | Merus N.V. | Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy |
| LT2346994T (lt) | 2008-09-30 | 2022-03-10 | Ablexis, Llc | Knock-in pelė, skirta chimerinių antikūnų gamybai |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| EP2564695B1 (en) | 2009-07-08 | 2015-04-15 | Kymab Limited | Animal models and therapeutic molecules |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| SMT201900251T1 (it) * | 2009-12-10 | 2019-07-11 | Regeneron Pharma | Topi che producono anticorpi della catena pesante |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| ES2603559T5 (es) | 2010-02-08 | 2021-02-22 | Regeneron Pharma | Cadena ligera común de ratón |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| EP2552957A4 (en) | 2010-03-29 | 2013-11-20 | Zymeworks Inc | ANTIBODIES WITH REINFORCED OR SUPPRESSIVE ACTIVE FUNCTION |
| WO2011123708A2 (en) | 2010-03-31 | 2011-10-06 | Ablexis Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
| CN104404050B (zh) | 2010-06-22 | 2018-06-08 | 瑞泽恩制药公司 | 杂交轻链小鼠 |
| RU2580017C2 (ru) | 2010-07-26 | 2016-04-10 | Трианни, Инк. | Трансгенные животные и способы применения |
| CA2807282A1 (en) | 2010-08-02 | 2012-02-09 | Regeneron Pharamaceuticals, Inc. | Mice that make binding proteins comprising vl domains |
| HUE047687T2 (hu) | 2011-02-25 | 2020-05-28 | Regeneron Pharma | ADAM6 egér |
| JP5893258B2 (ja) | 2011-03-31 | 2016-03-23 | フェリカネットワークス株式会社 | 情報処理装置および方法、並びにプログラム |
| US20130018582A1 (en) | 2011-07-13 | 2013-01-17 | Miller Paul A | Inertial Navigation Common Azimuth Reference Determination System and Method |
| FI3865581T3 (fi) | 2011-08-05 | 2024-11-02 | Regeneron Pharma | Humanisoituja universaaleja kevytketjun hiiriä |
| CN103945689B (zh) | 2011-09-19 | 2016-10-19 | 科马布有限公司 | 免疫球蛋白基因多样性的操纵及多抗体治疗剂 |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| KR102762747B1 (ko) | 2011-10-17 | 2025-02-05 | 리제너론 파마슈티칼스 인코포레이티드 | 제한된 면역글로불린 중쇄 마우스 |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| EP2771357B1 (en) * | 2011-10-28 | 2018-07-18 | Regeneron Pharmaceuticals, Inc. | Genetically modified t cell receptor mice |
| DK2770821T3 (da) | 2011-10-28 | 2017-11-27 | Regeneron Pharma | Genetisk modificerede major histocompatibility-kompleks-mus |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| EP2770822B9 (en) | 2011-10-28 | 2019-12-11 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
| BR112014008529A2 (pt) | 2011-10-28 | 2017-04-18 | Regeneron Pharma | il-6 humanizado e receptor de il-6 |
| WO2013063702A1 (en) | 2011-11-04 | 2013-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| US9120662B2 (en) | 2011-11-14 | 2015-09-01 | Susan A. Thomson | Gathering and dispensing scoop with gate valve |
| US9547499B2 (en) | 2011-12-09 | 2017-01-17 | Microsoft Technology Licensing, Llc | Device configuration with cached pre-assembled driver state |
| RS57118B1 (sr) | 2012-03-16 | 2018-06-29 | Regeneron Pharma | Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| CN104302170B (zh) * | 2012-03-16 | 2016-09-28 | 瑞泽恩制药公司 | 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠 |
| NZ730271A (en) | 2012-03-16 | 2022-09-30 | Regeneron Pharma | Non-human animals expressing ph-sensitive immunoglobulin sequences |
| JP5920830B2 (ja) | 2012-09-28 | 2016-05-18 | シスメックス株式会社 | 試料調製装置および細胞分析装置 |
| EP2931030B2 (en) | 2012-12-14 | 2024-01-17 | OmniAb, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
| TR201810255T4 (tr) * | 2013-02-20 | 2018-08-27 | Regeneron Pharma | Modifiye edilmiş immunoglobulin ağır zincir sekanslarına sahip olan insan olmayan hayvanlar. |
| EP3543253B1 (en) | 2013-02-20 | 2024-03-27 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| HRP20181866T1 (hr) | 2013-02-22 | 2019-01-25 | Regeneron Pharmaceuticals, Inc. | Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti |
| MX369747B (es) | 2013-04-16 | 2019-11-20 | Regeneron Pharma | Modificación dirigida del genoma de rata. |
| US9783618B2 (en) * | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| RU2685914C1 (ru) | 2013-12-11 | 2019-04-23 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
| SG11201607015VA (en) | 2014-03-21 | 2016-09-29 | Regeneron Pharma | V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS |
| CA3124228C (en) | 2014-03-21 | 2024-05-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
| HUE049776T2 (hu) | 2014-06-06 | 2020-10-28 | Regeneron Pharma | Módszerek és készítmények egy célzott lókusz módosítására |
| SMT202000184T1 (it) * | 2014-06-19 | 2020-05-08 | Regeneron Pharma | Animali non umani aventi un gene 1 della morte cellulare programmata umanizzato |
| DK3354732T3 (da) | 2014-06-23 | 2020-04-06 | Regeneron Pharma | Nukleasemedieret dna-samling |
| WO2015200805A2 (en) | 2014-06-26 | 2015-12-30 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
| AU2015317370A1 (en) * | 2014-09-19 | 2017-03-23 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
| WO2016164492A2 (en) | 2015-04-06 | 2016-10-13 | Regeneron Pharmaceuticals, Inc. | Humanized t cell mediated immune responses in non-human animals |
| KR102784608B1 (ko) | 2016-06-03 | 2025-03-27 | 리제너론 파마슈티칼스 인코포레이티드 | 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물 |
-
2017
- 2017-06-02 KR KR1020237037578A patent/KR102784608B1/ko active Active
- 2017-06-02 RU RU2018144954A patent/RU2753585C2/ru active
- 2017-06-02 MX MX2018014982A patent/MX385681B/es unknown
- 2017-06-02 US US15/612,625 patent/US10980221B2/en active Active
- 2017-06-02 SM SM20250152T patent/SMT202500152T1/it unknown
- 2017-06-02 IL IL263160A patent/IL263160B2/en unknown
- 2017-06-02 HR HRP20250471TT patent/HRP20250471T1/hr unknown
- 2017-06-02 CN CN202310402666.9A patent/CN116458475A/zh active Pending
- 2017-06-02 EP EP17733223.6A patent/EP3462853B1/en active Active
- 2017-06-02 SG SG11201810757YA patent/SG11201810757YA/en unknown
- 2017-06-02 SI SI201731599T patent/SI4218408T1/sl unknown
- 2017-06-02 EP EP23151094.2A patent/EP4218408B1/en active Active
- 2017-06-02 LT LTEP23151094.2T patent/LT4218408T/lt unknown
- 2017-06-02 RS RS20230395A patent/RS64216B1/sr unknown
- 2017-06-02 WO PCT/US2017/035731 patent/WO2017210586A1/en not_active Ceased
- 2017-06-02 PT PT231510942T patent/PT4218408T/pt unknown
- 2017-06-02 PT PT177332236T patent/PT3462853T/pt unknown
- 2017-06-02 LT LTEPPCT/US2017/035731T patent/LT3462853T/lt unknown
- 2017-06-02 CN CN201780048900.5A patent/CN109640644B/zh active Active
- 2017-06-02 KR KR1020187036917A patent/KR102483193B1/ko active Active
- 2017-06-02 DK DK23151094.2T patent/DK4218408T3/da active
- 2017-06-02 HU HUE17733223A patent/HUE061619T2/hu unknown
- 2017-06-02 BR BR112018074794-7A patent/BR112018074794A2/pt unknown
- 2017-06-02 PL PL23151094.2T patent/PL4218408T3/pl unknown
- 2017-06-02 SI SI201731323T patent/SI3462853T1/sl unknown
- 2017-06-02 ES ES17733223T patent/ES2941810T3/es active Active
- 2017-06-02 DK DK17733223.6T patent/DK3462853T3/da active
- 2017-06-02 FI FIEP23151094.2T patent/FI4218408T3/fi active
- 2017-06-02 KR KR1020227045806A patent/KR102598120B1/ko active Active
- 2017-06-02 ES ES23151094T patent/ES3018427T3/es active Active
- 2017-06-02 HU HUE23151094A patent/HUE071052T2/hu unknown
- 2017-06-02 SG SG10201914014XA patent/SG10201914014XA/en unknown
- 2017-06-02 FI FIEP17733223.6T patent/FI3462853T3/fi active
- 2017-06-02 HR HRP20230497TT patent/HRP20230497T1/hr unknown
- 2017-06-02 EP EP25156585.9A patent/EP4567104A3/en active Pending
- 2017-06-02 AU AU2017272337A patent/AU2017272337C1/en active Active
- 2017-06-02 CA CA3026088A patent/CA3026088A1/en active Pending
- 2017-06-02 RS RS20250364A patent/RS66700B1/sr unknown
- 2017-06-02 PL PL17733223.6T patent/PL3462853T3/pl unknown
- 2017-06-02 JP JP2018563156A patent/JP7053499B2/ja active Active
- 2017-06-02 CN CN202111170801.9A patent/CN113907043B/zh active Active
- 2017-06-02 SM SM20230132T patent/SMT202300132T1/it unknown
-
2018
- 2018-11-30 MX MX2021010351A patent/MX2021010351A/es unknown
- 2018-11-30 MX MX2021010352A patent/MX2021010352A/es unknown
-
2021
- 2021-03-16 US US17/203,398 patent/US12295354B2/en active Active
-
2022
- 2022-03-31 JP JP2022058938A patent/JP7274018B2/ja active Active
-
2023
- 2023-04-28 JP JP2023074624A patent/JP7586960B2/ja active Active
- 2023-05-31 CY CY20231100257T patent/CY1126063T1/el unknown
- 2023-07-30 IL IL304839A patent/IL304839A/en unknown
-
2024
- 2024-01-31 AU AU2024200577A patent/AU2024200577A1/en active Pending
- 2024-11-07 JP JP2024195337A patent/JP2025020339A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022088597A5 (enExample) | ||
| US20240057572A1 (en) | Animal Models and Therapeutic Molecules | |
| JP2018138047A5 (enExample) | ||
| JP2021137030A5 (enExample) | ||
| JP2019083823A5 (enExample) | ||
| JP2010529042A5 (enExample) | ||
| JP2020530760A5 (enExample) | ||
| JP2025105667A5 (enExample) | ||
| HRP20170322T1 (hr) | Miševi koji stvaraju vl vezne proteine | |
| JP2017509355A5 (enExample) | ||
| JP2014110814A5 (enExample) | ||
| JP2012532598A5 (enExample) | ||
| CA2532117A1 (en) | Humanized immunoglobulin loci | |
| JP2011182801A5 (enExample) | ||
| JP2015502177A5 (enExample) | ||
| RU2011129459A (ru) | Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение | |
| HUE029785T2 (en) | Common light chain mouse | |
| HUE034386T2 (en) | Generation of binding molecules | |
| JP2015505477A5 (enExample) | ||
| RU2019112589A (ru) | Отличные от человека животные со сконструированным локусом легкой лямбда-цепи иммуноглобулина | |
| EP4588345A1 (en) | Genetically modified non-human mammals, preparation methods therefor, and applications thereof | |
| Vora et al. | Altering the antibody repertoire via transgene homologous recombination: evidence for global and clone-autonomous regulation of antigen-driven B cell differentiation. | |
| JPWO2020169022A5 (enExample) | ||
| FI4023059T3 (fi) | Ei-ihmiseläimiä, jotka kykenevät DH-DH-uudelleenjärjestymiseen immunoglobuliinin raskasketjun koodaussekvensseissä | |
| JPWO2020247623A5 (enExample) |